Novo turns to Hengrui for another oral obesity drug
Novo has agreed to pay up to $2.6 billion for rights to a weight-loss pill, developed by China's Hengrui Pharma, that could be dosed just once a week.
Mirum puts Hepcludex in its sights with hep D readout
Gilead's Hepcludex was the first drug to be cleared in the US for hepatitis D in May, but a potential rival from Mirum Pharma is already looming.
AZ takes stake in Summit Therapeutics in $2bn deal
AstraZeneca has taken a roughly 10% stake in Summit and signed a deal to test CLDN18.2-targeting sone-ve with PD-1xVEGF bispecific ivonescimab.
FDA clears first drug for MCT8 deficiency
Sweden's Egetis has won approval in the US for the first-ever treatment for people living with the ultra-rare genetic disease MCT8 deficiency.
MSD takes a $400m bite of SciBrunch's KRAS drug
MSD has signed a license agreement for a KRAS G12D inhibitor from China's SciBrunch, paying $400m upfront for the preclinical candidate.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
CPHI Milan Leadership Summit returns for 2026
Senior pharma leaders will tackle resilience, policy, and industry transformation at CPHI Milan
Why Join The PM Society?
The professional organisation for people working in pharmaceutical marketing and healthcare communications, and why it's worth being part of.
Six Questions Shaping the Future of Health Innovation
The DIA-MHRA Global Summit explores six questions shaping the next decade of health innovation.
PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...
Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027
PMi Awards 2026 – The Winners and Highlights
Avalere Health is the night’s most awarded agency - Novo Nordisk, Roche, and The Urology Foundation top the client leaderboard